Qiagen has obtained premarket approval from the FDA for its Artus CMV QS-RGQ molecular diagnostic kit on the fully automated, sample-to-answer QiaSymphony platform. The real-time PCR assay, which is intended for use with human plasma samples, helps manage solid organ transplant patients who are on anti-cytomegalovirus therapy.
Qiagen's CMV assay on QiaSymphony platform OK'd by FDA
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.